Imunon
IMNN1.6003.90% ( +0.060 )
Imunon (IMNN)
Imunon, Inc., a clinical-stage biotechnology company, focuses on developing immunotherapies and vaccines in the United States. The company’s lead clinical progr...
- Open
- 1.660
- High
- 1.720
- Low
- 1.520
- Prev. Close
- 1.540
- Volume
- 665.49K
- Turnover
- 1.09M
- Avg Price
- 1.634
- Bid/Ask Ratio
- --
- Amplitude
- 12.99%
- 52wk High
- 8.191
- Volume Ratio
- 0.45
- Turnover Ratio
- 18.42%
Imunon Analyst Rating
View MoreForecast & Rating
Jul 21, 2026Price forecast
$17.00962.50%
Forecast & RatingStrong buy
4analysts
- Strong buy75.00%
- Buy25.00%
- Hold0.00%
- Sell0.00%
- Strong sell0.00%
News
- PUBT · 9 hours ago
Imunon says Phase 3 OVATION 3 ovarian cancer trial enrollment outpaces plan
- benzinga_article · 9 hours ago
EXCLUSIVE: Imunon Outlines Accelerated Timeline, Strong Safety Data for Pivotal Ovarian Cancer Study
- Global Report · Jul 26 at 04:18 AM
Beneath the Mega-Caps: Niche U.S. Equities Prep for H2 2026 Moves
- Global Report · Jul 26 at 04:14 AM
The Biotech Survival Charade: Stop Buying the "AI Pivot" Hype
- Global Report · Jul 25 at 04:13 AM
Divergent Fundamentals Across US Sectors: 2026 Mid-Year Operations Tracked
- Global Report · Jul 24 at 04:13 AM
Tech's Misfit Toys: Who's Actually Building and Who's Faking It?
